Payment overview · 2025
General Payments
$594.37
22 reported records · 5 companies
Healthcare provider profile · identity verified
Lisa Lee Kim
Allopathic & Osteopathic Physicians|Internal Medicine · VAN NUYS, CA · NPI 1104169796
Verified facts
What the public records show
CMS Open Payments records show Lisa Lee Kim received $594.37 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $230.96 | 38.9% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $143.71 | 24.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $116.25 | 19.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.06 | 10.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.39 | 7.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.37 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $122.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.99 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $116.25 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $108.97 | 6 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $82.43 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.10 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.39 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 843 | 244 |
| Amlodipine Besylate | Amlodipine Besylate | 612 | 173 |
| Losartan Potassium | Losartan Potassium | 395 | 107 |
| Metformin Hcl | Metformin Hcl | 338 | 98 |
| Omeprazole | Omeprazole | 224 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 56 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 180 | 58 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 162 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 34 |
| Vascepa | Icosapent Ethyl | 105 | 27 |
| Raloxifene Hcl | Raloxifene Hcl | 103 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 100 | 27 |
| Januvia | Sitagliptin Phosphate | 96 | 18 |
| Naproxen | Naproxen | 93 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 29 |
| Alendronate Sodium | Alendronate Sodium | 86 | 23 |
| Finasteride | Finasteride | 81 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 34 |
| Creon | Lipase/Protease/Amylase | 77 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 20 |
| Simvastatin | Simvastatin | 75 | 19 |
| Eliquis | Apixaban | 70 | 13 |
| Lisinopril | Lisinopril | 67 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 18 |
| Farxiga | Dapagliflozin Propanediol | 60 | 15 |
| Lidocaine | Lidocaine | 60 | 18 |
| Chlorthalidone | Chlorthalidone | 59 | 25 |
| Glipizide | Glipizide | 55 | 20 |
| Furosemide | Furosemide | 53 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 20 |
| Gabapentin | Gabapentin | 52 | 19 |
| Meloxicam | Meloxicam | 52 | 22 |
| Pregabalin | Pregabalin | 52 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 22 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 45 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 20 |
| Carvedilol | Carvedilol | 34 | 11 |
| Famotidine | Famotidine | 33 | 19 |
| Icosapent Ethyl | Icosapent Ethyl | 33 | 16 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 25 |
| Trazodone Hcl | Trazodone Hcl | 31 | 17 |
| Hydrocortisone | Hydrocortisone | 30 | 11 |
| Mirtazapine | Mirtazapine | 30 | 13 |
| Estradiol | Estradiol | 29 | 17 |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 26 | suppressed |
| Prolia | Denosumab | 26 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 16 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 11 |
| Mupirocin | Mupirocin | 20 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 12 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $594.37 · 22 records | Amgen Inc. | CAPVAXIVE, Cologuard Collection Kit, EVENITY, FARXIGA, GARDASIL 9, JARDIANCE, OTEZLA, REPATHA, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error